A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SIR4156, a novel NAMPT activator, in healthy adult and elderly participants.
Latest Information Update: 03 Nov 2025
At a glance
- Drugs SIR 4156 (Primary)
- Indications Musculoskeletal disorders
- Focus Adverse reactions; First in man
- Sponsors Sironax Aus Pty
Most Recent Events
- 03 Nov 2025 New trial record
- 23 Oct 2025 According to a Sironax media release, the company has three clinical-stage programs and is currently conducting clinical studies with SIR2501, SIR4156, and SIR9900.